Current advances in development of new docetaxel formulations

doi:10.1080/17425247.2019.1583644

IOCAS-IR > 实验海洋生物学重点实验室

	Current advances in development of new docetaxel formulations
	Zhang, Enhui1,2,3 ; Xing, Ronge1,2,3 ; Liu, Song 1,2,3; Li, Pengcheng1,2,3
	2019-03-04
发表期刊	EXPERT OPINION ON DRUG DELIVERY
ISSN	1742-5247
卷号	16 期号:3 页码:301-312
通讯作者	Xing, Ronge(xingronge@qdio.ac.cn) ; Li, Pengcheng(pcli@qdio.ac.cn)
摘要	Introduction: Docetaxel (DTX) is one of the most important chemotherapeutic agents and has been widely used for treatment of various types of cancers. However, the clinical chemotherapy of DTX gives many undesirable side effects due to the usage of organic solvent in the injection and its low selectivity for tumor cells. With the evolution of pharmaceutical technologies, great efforts have been paid to develop new DTX formulations to overcome these problems. Areas covered: This review provided an overview of the preparation and activities of new DTX formulations, which were classified by administration methods, including injection, oral, transdermal and rectal administration. Besides, up to date information of the clinical status of new DTX formulations was summarized. We also discussed the challenges and perspectives of the future development of DTX formulations. Expert opinion: There have been numerous studies on new DTX-based formulations in recent years, and many of them exhibited significantly enhanced anti-tumor and targeting activity compared with DTX in preclinical studies. However, only a few entered clinical trials, and none has been approved into market. The clinical translation of experimental drug faces many hurdles, including the limited knowledge of nanomedicine and oncology, safety issues, controllable and reproducible production.
关键词	Docetaxel drug delivery system targeting liposome nanoparticle
DOI	10.1080/17425247.2019.1583644
收录类别	SCI
语种	英语
资助项目	Special projects of Foshan science and technology innovation team[2017IT100054] ; National Key R&D Program of China[2018YFC0311305] ; National Key R&D Program of China[2018YFC0311305] ; Special projects of Foshan science and technology innovation team[2017IT100054]
WOS研究方向	Pharmacology & Pharmacy
WOS类目	Pharmacology & Pharmacy
WOS记录号	WOS:000461429100009
出版者	TAYLOR & FRANCIS LTD
引用统计	被引频次：38[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.qdio.ac.cn/handle/337002/155223
专题	实验海洋生物学重点实验室
通讯作者	Xing, Ronge; Li, Pengcheng
作者单位	1.Chinese Acad Sci, Inst Oceanol, CAS Key Lab Expt Marine Biol, Qingdao, Peoples R China 2.Qingdao Natl Lab Marine Sci & Technol, Lab Marine Drugs & Bioprod, Qingdao, Peoples R China 3.Chinese Acad Sci, Ctr Ocean Mega Sci, Qingdao, Peoples R China
第一作者单位	中国科学院海洋研究所
通讯作者单位	中国科学院海洋研究所
推荐引用方式 GB/T 7714	Zhang, Enhui,Xing, Ronge,Liu, Song,et al. Current advances in development of new docetaxel formulations[J]. EXPERT OPINION ON DRUG DELIVERY,2019,16(3):301-312.
APA	Zhang, Enhui,Xing, Ronge,Liu, Song,&Li, Pengcheng.(2019).Current advances in development of new docetaxel formulations.EXPERT OPINION ON DRUG DELIVERY,16(3),301-312.
MLA	Zhang, Enhui,et al."Current advances in development of new docetaxel formulations".EXPERT OPINION ON DRUG DELIVERY 16.3(2019):301-312.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
Corrosion of Copper-（1550KB）	期刊论文	出版稿	限制开放	CC BY-NC-SA	浏览